Literature DB >> 24113781

Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis.

Tohru Iwahori1, Masatoshi Esaki, Hayao Hinoue, Shinga Esaki, Yukumi Esaki.   

Abstract

BACKGROUND: Hypoalbuminemia caused by peritoneal dialysate protein loss, frequently occurs in patients on peritoneal dialysis (PD) and is associated with an increased risk of death. We investigate whether PD dialysis exchange volume (PD volume) could be reduced with tolvaptan (TVP) through increased urine volume (UV).
METHODS: The study included 11 stable patients with oliguria undergoing PD. The following parameters were examined-diuretic response and the effect of TVP on peritoneal ultrafiltration (UF), body weight, serum albumin, sodium, arm muscle area (AMA), PD volume, dialysis efficiency calculator (K t/V), and urine and serum osmolarity (OSM).
RESULTS: The average UV increased from 428 ± 178 to 906 ± 285 mL (p = 0.018 by paired t test). Average weekly PD volume decreased from 28,836 ± 5,699 to 23,872 ± 3,569 mL (p = 0.04 by paired t test). Average UF increased from 283 ± 147 to 575 ± 135 mL (p = 0.019 by paired t test). On the other hand, there was no significant difference in the average dialysate K t/V before and after TVP treatment. Serum sodium, AMA, and serum albumin levels were not statistically different before and after TVP treatment. The urine and serum OSM ratio of effective cases before TVP treatment was higher than that of ineffective cases (p = 0.024 by unpaired t test).
CONCLUSION: Our results indicate that TVP is useful for patients on continuous ambulatory PD who have oliguria and high urine osmolarity. Furthermore, we can reduce PD volume to maintain their nutritional status.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24113781     DOI: 10.1007/s10157-013-0883-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  23 in total

1.  Peritoneal protein losses do not have a significant impact on nutritional status in CAPD patients.

Authors:  K Ateş; A Oztemel; G Nergizoğlu; S Ertürk; K Keven; H Akar; O Karatan; N Duman; B Erbay; A E Ertuğ
Journal:  Perit Dial Int       Date:  2001 Sep-Oct       Impact factor: 1.756

2.  Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure.

Authors:  Jeffrey M Testani; Thomas P Cappola; Colleen M Brensinger; Richard P Shannon; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

Review 3.  Non-peptide arginine-vasopressin antagonists: the vaptans.

Authors:  Guy Decaux; Alain Soupart; Gilbert Vassart
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

Review 4.  Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives.

Authors:  Hoey Lan Tjiong; Roel Swart; Jacobus W van den Berg; Marien W Fieren
Journal:  Perit Dial Int       Date:  2009 Jul-Aug       Impact factor: 1.756

5.  Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.

Authors:  Kiyotaka Watanabe; Kaoru Dohi; Tadafumi Sugimoto; Tomomi Yamada; Yuichi Sato; Kazuhide Ichikawa; Emiyo Sugiura; Naoto Kumagai; Shiro Nakamori; Hiroshi Nakajima; Kozo Hoshino; Hirofumi Machida; Shinya Okamoto; Katsuya Onishi; Mashio Nakamura; Tsutomu Nobori; Masaaki Ito
Journal:  J Cardiol       Date:  2012-10-12       Impact factor: 3.159

Review 6.  Peritoneal dialysis first: rationale.

Authors:  Kunal Chaudhary; Harbaksh Sangha; Ramesh Khanna
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 8.237

7.  Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R.

Authors:  John H Boyd; Cheryl L Holmes; Yingjin Wang; Haley Roberts; Keith R Walley
Journal:  Resuscitation       Date:  2008-11       Impact factor: 5.262

8.  Protein losses during peritoneal dialysis.

Authors:  M J Blumenkrantz; G M Gahl; J D Kopple; A V Kamdar; M R Jones; M Kessel; J W Coburn
Journal:  Kidney Int       Date:  1981-04       Impact factor: 10.612

Review 9.  Vasopressin-receptor antagonists in heart failure.

Authors:  Teresa A Schweiger; Martin M Zdanowicz
Journal:  Am J Health Syst Pharm       Date:  2008-05-01       Impact factor: 2.637

10.  Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.

Authors:  Susan E Shoaf; Steven L Bramer; Patricia Bricmont; Christopher A Zimmer
Journal:  J Cardiovasc Pharmacol       Date:  2007-08       Impact factor: 3.105

View more
  1 in total

1.  Intrarenal renin-angiotensin system activity is augmented after initiation of dialysis.

Authors:  Naro Ohashi; Shinsuke Isobe; Sayaka Ishigaki; Takahisa Suzuki; Masafumi Ono; Tomoyuki Fujikura; Takayuki Tsuji; Akihiko Kato; Seiichiro Ozono; Hideo Yasuda
Journal:  Hypertens Res       Date:  2016-10-20       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.